Results 211 to 220 of about 34,220 (292)

Investigation of risk factors for autism spectrum disorder in children with tuberous sclerosis complex. [PDF]

BMC Psychiatry
Hu J, Zhao C, Fang Y, Zhang H, Liao J.
europepmc   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

ENT1 inhibitor J4 restores cognitive function and white-matter integrity in a mouse model of tuberous sclerosis complex. [PDF]

J Biomed Sci
Hsieh CC, Tsou YS, Huang NK, Chen TC, Li SJ, Chang CW, Lin WX, Tung SY, Chern Y, Chen YY, Lee YC.   +10 more
europepmc   +1 more source

Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley   +1 more source

NEAT1 Promotes Epileptogenesis in Tuberous Sclerosis Complex. [PDF]

Adv Sci (Weinh)
Kuang S, Liu T, Wei Z, Xu J, Han J, Wang J, Zhai F, Tian Y, Liang S.   +8 more
europepmc   +1 more source

Smart bio-implants for seizure prediction in tuberous sclerosis complex. [PDF]

Ann Med Surg (Lond)
Panhwar DM, Rasheed Siddiqui A, Mudasir Atif M, Jaber Amin MH.   +3 more
europepmc   +1 more source

Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1‐Related Disorders

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Syntaxin‐binding protein 1 (STXBP1) mutations lead to severe epilepsy, intellectual disability, developmental delay, and movement disorder. Effective treatments for these conditions do not exist. Recent studies in Munc18‐1 (STXBP1) C. elegans models demonstrate that 4‐phenylbutyrate (4‐PBA) or related pharmacological chaperones stabilize ...
Aline Frick, Paige Whyte‐Fagundes, Scott C. Baraban   +2 more
wiley   +1 more source

Tuberous sclerosis presents with self-injurious behavior as an adverse event of Vigabatrin. [PDF]

Indian J Psychiatry
Meghana V, Sakhardande KA, Thomas TL.
europepmc   +1 more source

High prevalence of orocutaneous features in Yemeni patients with tuberous sclerosis complex. [PDF]

JAAD Int
Alshami MA, Al-Shami AM, Mohana MJ, Mohammed Al-Sayaghi AA, Alshami HM.   +4 more
europepmc   +1 more source